Gelatine and collagen manufacturer PB Leiner will attend the show to discuss its recently completed clinical study which concludes that consuming its Solugel collagen peptides can bring about significant reductions in joint pain and discomfort in active middle-aged adults.
Carried out by Florida State University (FSU) (commissioned by PB Leiner), study participants (aged 45-65) consumed either a placebo or Solugel collagen peptides (10g) every day over the course of six months.
Those consuming Solugel collagen peptides saw a 36% improvement according to the Knee Injury and Osteoarthritis Outcome Score, indicating significant reductions in pain and improvement in knee functionality. By contrast, more than half of those in the placebo group saw a decline in their score.
The study, due to be published later in ‘Journal of the International Society of Sports Nutrition Supplement’, also found that collagen peptides may improve the ability to carry out everyday tasks such as commuting, cleaning and shopping. A third of those consuming 10g of Solugel collagen peptides each day saw clinically meaningful improvements in their scores while undertaking such activities while none of the participants in the placebo group saw any improvement.
The study is the first to prove collagen’s long-term impact on both joint pain and everyday activities in the healthy and active middle-aged population.
Dr. Mike Ormsbee, Associate Director at FSU Institute of Sports Sciences & Medicine and the lead clinical study researcher, said: “This is the first and only study to examine the impact of collagen peptides on joint pain in this demographic group. The findings suggest they have protective as well as beneficial effects, supporting the growth and repair of connective tissue as well as reducing joint pain.”